BEIJING, July 15 China Medical Technologies,Inc. (the "Company") (Nasdaq: CMED), a leading China-based advanced in-vitrodiagnostic ("IVD") company, today announced that its HER-2 FISH probe has beenchosen to be used in a research project focusing on cancer targeted therapystandardization, as well as early cancer detection and treatment, which issponsored by the Chinese Ministry of Health. One of the subjects of thisresearch project is to standardize the process and procedures for the use ofFISH technology to detect HER-2 gene amplification in breast cancer andstomach cancer patients to guide the use of Herceptin (the "HER-2 Study"). TheCompany is the supplier of HER-2 FISH probe for the HER-2 Study.
Immunohistochemistry used to be the traditional diagnostic method indetecting HER-2 gene amplification in China, but it has false positive andfalse negative results. The HER-2 Study is the first study in China to includeFISH technology as the gold standard in HER-2 gene amplification detection.The Company believes that the results of the HER-2 Study may contribute tomore widespread use of its HER-2 FISH probe in the companion diagnostic testmarket in China for guiding treatment for breast cancer and stomach cancer.According to the Chinese Central Government's Official Web Portal, about200,000 new cases of breast cancer and 400,000 new cases of stomach cancer arediagnosed in China each year.
"We believe that our selection as the supplier of HER-2 FISH probe in theHER-2 Study by the top ranking cancer research institute demonstrates the goodquality of our HER-2 FISH probe," commented Mr. Xiaodong Wu, Chairman andChief Executive Officer of the Company.
The HER-2 Study is led by the Cancer Institute and Hospital of the ChineseAcademy of Medical Sciences with Dr. Yuankai Shi as the principal investigator.
About China Medical Technologies, Inc.
China Medical Technologies, Inc. is a leading China-based advanced IVDcompany using molecular diagnostic technologies including Fluorescent in situHybridization (FISH) and Surface Plasmon Resonance (SPR) and animmunodiagnostic technology, Enhanced Chemiluminescence Immunoassay (ECLIA),to develop, manufacture and distribute diagnostic products used for thedetection of various cancers, diseases and disorders as well as companiondiagnostic tests for targeted cancer drugs. The Company generates all of itsrevenues in China through the sale of diagnostic consumables including FISHprobes, SPR-based DNA chips and ECLIA reagent kits to hospitals which arerecurring users of the consumables for their patients. The Company sells FISHprobes and SPR chips to large hospitals through its direct sales force andECLIA reagent kits to small and mid-size hospitals through distributors. Formore information, please visit http://www.chinameditech.com .
Safe Harbor Statement
This press release contains forward-looking statements. These statementsconstitute "forward-looking" statements within the meaning of Section 21E ofthe Securities Exchange Act of 1934, as amended, and as defined in the U.S.Private Securities Litigation Reform Act of 1995. These forward-lookingstatements can be identified by terminology such as "will," "expects,""anticipates," "future," "intends," "plans," "believes," "estimates" andsimilar statements. Such statements involve certain risks and uncertaintiesthat could cause actual results to differ materially from those in theforward-looking statements, including the risk that the results of the HER-2Study will not lead to increased use of the Company's HER-2 FISH probe.Further information regarding these and other risks is included in theCompany's filings with the U.S. Securities and Exchange Commission, includingits annual report on Form 20-F. The Company does not undertake any obligationto update any forward-looking statement as a result of new information, futureevents or otherwise, except as required under applicable law.For more information, please contact: Winnie Yam Phone: +852-2511-9808 Email: IR@chinameditech.com
SOURCE China Medical Technologies, Inc.